SCHEMBL30765729

SCHEMBL30765729

C[C@@H](Nc1ncc(Br)n(CC(=O)OC(C)(C)C)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
JAK3 P52333 1/20 0.36
LMNA P02545 3/20 0.35
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34
GABRA4 P48169 1/20 0.34
GABRE P78334 1/20 0.34
GABRA6 Q16445 1/20 0.34
GABRG1 Q8N1C3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765802 0.86 GAA (0.40) ALDH1A1LMNAGABRPGABRDGABRA1
SCHEMBL30766072 0.86 SOS1 (0.39) ALDH1A1KDM4EJAK2JAK1JAK3
SCHEMBL30765521 0.83 KMT2A (0.38) ALDH1A1KDM4ELMNAKMT2ANPSR1
SCHEMBL30765893 0.83 ALDH1A1 (0.33) ALDH1A1KDM4EJAK2JAK1JAK3
SCHEMBL30765957 0.83 ALDH1A1 (0.38) ALDH1A1KDM4EJAK2JAK1JAK3
SCHEMBL30765962 0.82 KMT2A (0.35) ALDH1A1KDM4ELMNAKMT2ANPSR1
SCHEMBL30765941 0.81 ALDH1A1 (0.37) ALDH1A1KDM4EJAK2JAK1JAK3
SCHEMBL30765931 0.81 ALDH1A1 (0.37) ALDH1A1KDM4EJAK2JAK1JAK3
SCHEMBL30765995 0.81 ALDH1A1 (0.37) ALDH1A1KDM4EJAK2JAK1JAK3
SCHEMBL30765991 0.81 ELANE (0.42) ALDH1A1KDM4EJAK2JAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed